✨ Free AI Report
GENFIT: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research GENFIT
Company Research

GENFIT: Business Overview, Financials & Competitive Analysis

GENFIT scores 7/10 on the AskCyborg Cyborg Score (Strong). GENFIT has secured first regulatory approval of Iqirvo®, demonstrated strong cash position, and progressing ACLF pipeline with recent positive Phase 1 data. As of December 31, 2025, the Company's cash and cash equivalents amounted to €101.1 million. GENFIT expects that its existing cash and cash equivalents will enable the Company to.

What is GENFIT's industry? GENFIT (genfit.com) operates in Specialty Biopharmaceuticals (Rare Liver Diseases). AskCyborg classifies GENFIT under Specialty Biopharmaceuticals (Rare Liver Diseases) in its company registry.

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. In 2024, GENFIT achieved accelerated approval of ...

7/ 10Strong

Cyborg Score thesis

GENFIT has secured first regulatory approval of Iqirvo®, demonstrated strong cash position, and progressing ACLF pipeline with...

Read the full analyst-debate transcript →
Industry Specialty Biopharmaceuticals (Rare Liver Diseases)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest GENFIT Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for GENFIT

AskCyborg analysts argue the bull and bear cases for GENFIT across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
GENFIT OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

GENFIT Overview

Pro stress-test →

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. In 2024, GENFIT achieved accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of Primary Biliary Cholangitis (PBC). Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH).

Strategic Profile

Pro stress-test →

GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE), developing therapeutic assets with complementary mechanisms of action, and also targets other serious diseases such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital.

Competitive Landscape

Pro stress-test →

GENFIT addresses the rare liver disease market with unmet medical needs. The company competes in specialized sectors: Primary Biliary Cholangitis (through approved Iqirvo®), ACLF treatment candidates, and liver disease diagnostics. Key competitive advantage stems from its long heritage in liver disease research and recent regulatory approval of its lead asset.

Industry Context

GENFIT operates in Specialty Biopharmaceuticals (Rare Liver Diseases).

Key facts

Founded: 1999 · Headquarters: Lille, France · Revenue: €65.4 million

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on GENFIT.

  • Ipsen's strong performance with Iqirvo® generated >$200M net sales in year one, triggering GENFIT's milestone payment.
  • Cash position increased to €101.1 million by year-end 2025, supported by €26.55 million milestone received upon pricing approval of Iqirvo® in Italy.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Cash position of €101.1 million reported as of December 31, 2025.
  • January 2026G1090N demonstrated favorable Phase 1 safety profile and strong anti-inflammatory activity.
  • +1 moreTrack every material event for GENFIT as it happens. Explore monitoring →
Get alerted when GENFIT has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Obeticholic acidPBC treatment (competitor to Iqirvo®)→Various NASH/MASH programsCompeting in metabolic liver disease diagnostics and therapeutics→GLP-1 therapiesEmerging treatments for metabolic liver conditions→

Compare GENFIT with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GENFIT operates in Specialty Biopharmaceuticals (Rare Liver Diseases). See how the rest of the sector scores on the Cyborg framework.

Browse Specialty Biopharmaceuticals (Rare Liver Diseases) research →
NEW · MCP server

Ask your AI assistant about GENFIT

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GENFIT and its top competitor on Cyborg Score”
“What did GENFIT do this quarter?”
“Is GENFIT a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does GENFIT do?+
GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. In 2024, GENFIT achieved accelerated approval of ...
What is GENFIT's Cyborg Score?+
GENFIT has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GENFIT's main competitors?+
Named competitors include Obeticholic acid, Various NASH/MASH programs, GLP-1 therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full GENFIT research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GENFIT research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GENFIT over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Biopharmaceuticals (Rare Liver Diseases) research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7GENFIT